Aptamer Group PLC Issue of Equity and Total Voting Rights (7493M)
16 January 2023 - 6:00PM
UK Regulatory
TIDMAPTA
RNS Number : 7493M
Aptamer Group PLC
16 January 2023
16 January 2023
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Issue of Equity and Total Voting Rights
Aptamer Group plc (AIM: APTA), the developer of novel Optimer
(R) binders to enable innovation in the life sciences industry,
announces that it has issued 10,000 new ordinary shares in order to
satisfy the exercise of share options.
Application for the admission of these shares to trading on AIM
has been made and admission is expected on Thursday 19 January
2023, following which the total number of ordinary shares in issue
and total voting rights will be 69,047,594 . The Group does not
hold any shares in treasury and, therefore, the above figure may be
used by shareholders as the denominator for the calculation by
which they will determine if they are required to notify their
interest in, or a change to their interest in the Company.
For further information, please contact:
Aptamer Group plc
Dr Arron Tolley +44 (0) 1904 217 404
SPARK Advisory Partners Limited - Nominated Adviser
Andrew Emmott / Adam Dawes +44 (0) 20 3368 3550
Liberum Capital Limited - Broker
Richard Lindley / Ben Cryer / Cara Murphy +44 (0) 20 3100 2000
Consilium Strategic Communications
Matthew Neal / Chris Welsh / Lucy Featherstone +44 (0) 20 3709 5700
aptamergroup@consilium-comms.com
About Aptamer Group plc
Aptamer Group develops custom affinity binders through its
proprietary Optimer (R) platform to enable new approaches in
therapeutics, diagnostics and research applications. The Company
strives to deliver transformational solutions that meet the needs
of life science researchers and developers through the use of its
proprietary Optimer platform.
Optimer binders are oligonucleotide affinity ligands that can
function as an antibody alternative. The global antibody market is
currently worth over $145.0 billion. Optimer binders are engineered
to address many of the issues found with alternative affinity
molecules, such as antibodies, and offer new, innovative solutions
to bioprocessing, diagnostic and pharmaceutical scientists.
Aptamer Group has successfully delivered projects for global
pharma companies, diagnostic development companies, and research
institutes covering a range of targets and applications with the
objective of establishing royalty-bearing licenses. Through the
unique Optimer technology and processes, scientists and
collaborators are enabled to make faster, more informed decisions
that support discovery and development across the Life
Sciences.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEBIGDBRBBDGXU
(END) Dow Jones Newswires
January 16, 2023 02:00 ET (07:00 GMT)
Aptamer (LSE:APTA)
Historical Stock Chart
From Apr 2024 to May 2024
Aptamer (LSE:APTA)
Historical Stock Chart
From May 2023 to May 2024